Bristol’s CAR-T Strategy Comes Into Focus With Two Near-Term Filings

In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration — Bristol is expanding its CAR-T cell development into new indications.

Bristol-Myers Squibb Co., after completing its acquisition of Celgene Corp., is attempting to position itself as a developer of best-in-class and first-in-class chimeric antigen receptor T-cell (CAR-T) therapies for lymphoma and multiple myeloma, including the CD19-targeting lisocabtagene maraleucel (JCAR017, liso-cel) and idecabtagene vicleucel (ide-cel, bb2121) against B-cell maturation antigen (BCMA).

The company presented pivotal trial results in relapsed and refractory B-cell lymphoma for its first CAR-T therapy, liso-cel, at the...